IL-1 mediates TNF-induced osteoclastogenesis

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 282-290

  Wei, Shi ^a   Kitaura, Hideki ^a   Zhou, Ping ^a   Patrick Ross, F ^a   Teitelbaum, Steven L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COLONY STIMULATING FACTOR 1; I KAPPA B ALPHA; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; CARRIER PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; STEM CELL; STROMA CELL; ANIMAL; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SIGNAL TRANSDUCTION;

ANIMALS; BONE MARROW CELLS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION; INTERLEUKIN-1; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOLYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; STEM CELLS; STROMAL CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14944371405     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200523394     Document Type: Article

References (27)

1. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science. 289:1504-1508.
2. Ross, P.P. 2000. RANKing the importance of measles virus in Paget's disease. J. Clin. Invest. 105:555-558.
3. Locklin, R.M., Khosla, S., Turner, R.T., and Riggs, B.L. 2003. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell. Biochem. 89:180-190.
4. Feldmann, M., and Maini, R.N. 2001. Anti-TNF therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol. 19:163-196.
5. Gravallese, E.M. 2002. Bone destruction in arthritis. Ann. Rheum. Dis. 61(Suppl. 2):ii84-ii86.
6. Romas, E., Gillespie, M.T., and Martin, T.J. 2002. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 30:340-346.
7. Redlich, K., et al. 2002. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110:1419-1427. doi:10.1172/JCI200215582.
8. Ritchlin, C.T., Haas-Smith, S.A., Li, P., Hicks, D.G., and Schwarz, E.M. 2003. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111:821-831. doi:10.1172/JCI200316069.
9. Lam, J., et al. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488.
10. Li, P., et al. 2004. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi)osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J. Bone Miner. Res. 19:207-213.
11. Hofbauer, L.C., et al. 1999. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:255-259.
12. Dayer, J.M. 2002. Interleukin 1 or tumor necrosis factor-a: which is the real target in rheumatoid arthritis. J. Rheumatol. 29(Suppl. 65):10-15.
13. Arend, W.P. 2002. The mode of action of cytokine inhibitors. J. Rheumatol. 29(Suppl.):16-21.
14. Zwerina, J., et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50:277-290.
15. Kitaura, H., et al. 2004. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α induced osteoclastogenesis in vivo. J. Immunol. 173:4838-4846.
16. Brennan, P.M., Chantry, D., Jackson, A., Maini, R., and Feldmann, M. 1989. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:244-247.
17. Dinarello, C.A. 1996. Biologic basis for interleukin-1 in disease. Blood. 87:2095-2147.
18. Dunne, A., and O'Neill, L.A.J. 2003. The interleukin-1 receptor/toll-like receptor superfamily: signal transduction during inflammation and host defense [review]. Sci. STKE. 171:3.
19. Wei, S., Wang, M.W., Teitelbaum, S.L., and Ross, P.P. 2002. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and MAP kinase signaling. J. Biol. Chem. 21:6622-6630.
20. Jimi, E., et al. 1999. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93.
21. Matsumoto, M., Sudo, T., Maruyama, M., Osada, H., and Tsujimoto, M. 2000. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett. 486:23-28.
22. Li, X., et al. 2003. p38 mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology. 144:4999-5005.
23. Badger, A.M., et al. 2000. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 43:175-183.
24. Nishikawa, M., et al. 2003. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 48:2670-2681.
25. Badger, A., et al. 1996. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279:1453-1461.
26. Ishida, N., et al. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277:41147-41156.
27. McHugh, K.P., et al. 2000. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105:433-440.